acute lymphoblastic leukemia
Conditions
Brief summary
The proportion of patients achieving complete remission (CR) with MRD level <0.1% of bone marrow cells after one course of induction treatment
Detailed description
The proportion of patients achieving CR with MRD level <0.01% of bone marrow cells after consolidation., CR rate after Induction I., Overall CR rate in 24 month follow-up., Probability of overall survival (OS) in 24 month follow-up, Probability of relapse-free survival (RFS) in 24 month follow-up, Probability of event-free survival (EFS) in 24 month follow-up, Cumulative incidence of relapse in 24 month follow-up, Rate of adverse events in 24 month follow-up.
Interventions
DRUGOBINUTUZUMAB
DRUGRITUXIMAB
Sponsors
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of patients achieving complete remission (CR) with MRD level <0.1% of bone marrow cells after one course of induction treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| The proportion of patients achieving CR with MRD level <0.01% of bone marrow cells after consolidation., CR rate after Induction I., Overall CR rate in 24 month follow-up., Probability of overall survival (OS) in 24 month follow-up, Probability of relapse-free survival (RFS) in 24 month follow-up, Probability of event-free survival (EFS) in 24 month follow-up, Cumulative incidence of relapse in 24 month follow-up, Rate of adverse events in 24 month follow-up. | — |
Countries
Poland
Outcome results
None listed